Road Maps to Achieve Glycemic Control in Type 2 Diabetes Mellitus
- 1 May 2007
- journal article
- practice guideline
- Published by Elsevier BV in Endocrine Practice
- Vol. 13 (3), 260-268
- https://doi.org/10.4158/ep.13.3.260
Abstract
No abstract availableThis publication has 71 references indexed in Scilit:
- The Combined Effect of Triple Therapy With Rosiglitazone, Metformin, and Insulin Aspart in Type 2 Diabetic PatientsDiabetes Care, 2003
- Long-Term Efficacy of Triple Oral Therapy for Type 2 Diabetes MellitusEndocrine Practice, 2002
- Effect of Metformin and Rosiglitazone Combination Therapy in Patients With Type 2 Diabetes MellitusJAMA, 2000
- Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin.Diabetes Care, 2000
- Addition of low‐dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patientsDiabetic Medicine, 2000
- Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.Diabetes Care, 1999
- The evolving role of α-glucosidase inhibitorsDiabetes/Metabolism Research and Reviews, 1998
- Triple Oral Antidiabetic Therapy in Type 2 Diabetes MellitusEndocrine Practice, 1998
- European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: efficacy and safety of low and high doses.Acta Diabetologica, 1998
- Therapeutic Potentials of Acarbose as First-Line Drug in NIDDM Insufficiently Treated With Diet AloneDiabetes Care, 1991